Charles Gayer
Fortune : 4 M $ au 30/06/2026
Fortune : 4 M $ au 30/06/2026
Charles K.
Gayer is President, Chief Executive Officer & Director at BioCryst Pharmaceuticals, Inc. since 2026.
Formerly, Mr. Gayer was Head-US & Global Commercial Business at Grifols Therapeutics, Inc. Education includes an undergraduate degree from Princeton University and an MBA from The Fuqua School of Business.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 13/04/2026 | 364 620 ( 0,14 % ) | 4 M $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Directeur Général | 01/01/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
Grifols Therapeutics, Inc.
Grifols Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops therapeutic products | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. BiotechnologyHealth Technology Designs and develops oral small-molecule & injectable protein therapeutics | Health Technology |
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Grifols Therapeutics, Inc.
Grifols Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops therapeutic products | Health Technology |
The Fuqua School of Business
The Fuqua School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national